Literature DB >> 8987758

GDNF reduces drug-induced rotational behavior after medial forebrain bundle transection by a mechanism not involving striatal dopamine.

J L Tseng1, E E Baetge, A D Zurn, P Aebischer.   

Abstract

Parkinson's disease (PD) is characterized by the progressive loss of the substantia nigra (SN) dopaminergic neurons projecting to the striatum. Neurotrophic factors may have the potential to prevent or slow down the degenerative process occurring in PD. To that end, we examined whether low amounts of glial cell line-derived neurotrophic factor (GDNF) continuously released from polymer-encapsulated genetically engineered cells are able to prevent the loss of tyrosine hydroxylase immunoreactivity (TH-IR) in SN neurons and ameliorate the amphetamine-induced rotational asymmetry in rats that have been subjected to a unilateral medial forebrain bundle (MFB) axotomy. Baby hamster kidney (BHK) cells transfected with the cDNA for GDNF were encapsulated in a polymer fiber and implanted unilaterally at a location lateral to the MFB and rostral to the SN. ELISA assays before implantation show that the capsules release approximately 5 ng of GDNF/capsule per day. One week later, the MFB was axotomized unilaterally ipsilateral to the capsule placement. Seven days later, the animals were tested for amphetamine-induced rotational asymmetry and killed. The striatum was excised and analyzed either for catecholamine content or TH-IR, while the SN was immunostained for the presence of TH-IR. GDNF did not prevent the loss of dopamine in the striatum. However, GDNF significantly rescued TH-IR neurons in the SN pars compacta. Furthermore, GDNF also significantly reduced the number of turns per minute ipsilateral to the lesion under the influence of amphetamine. Improvement of rotational behavior in the absence of dopaminergic striatal reinnervation may reflect neuronal plasticity in the SN, as suggested by the dendritic sprouting observed in animals receiving GDNF. These results illustrate that the continuous release of low levels of GDNF close to the SN is capable of protecting the nigral dopaminergic neurons from an axotomy-induced lesion and significantly improving pharmacological rotational behavior by a mechanism other than dopaminergic striatal reinnervation.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 8987758      PMCID: PMC6793689     

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.167


  30 in total

1.  Estimation of nuclear population from microtome sections.

Authors:  M ABERCROMBIE
Journal:  Anat Rec       Date:  1946-02

2.  A quantitative study of cell death in the substantia nigra following a mechanical lesion of the medial forebrain bundle.

Authors:  J E Brecknell; S B Dunnett; J W Fawcett
Journal:  Neuroscience       Date:  1995-01       Impact factor: 3.590

3.  Behavioural effects and supersensitivity following nigral dopamine receptor stimulation.

Authors:  M R Kozlowski; S Sawyer; J F Marshall
Journal:  Nature       Date:  1980-09-04       Impact factor: 49.962

4.  Intrathecal delivery of CNTF using encapsulated genetically modified xenogeneic cells in amyotrophic lateral sclerosis patients.

Authors:  P Aebischer; M Schluep; N Déglon; J M Joseph; L Hirt; B Heyd; M Goddard; J P Hammang; A D Zurn; A C Kato; F Regli; E E Baetge
Journal:  Nat Med       Date:  1996-06       Impact factor: 53.440

5.  Brain-derived neurotrophic factor administration protects basal forebrain cholinergic but not nigral dopaminergic neurons from degenerative changes after axotomy in the adult rat brain.

Authors:  B Knüsel; K D Beck; J W Winslow; A Rosenthal; L E Burton; H R Widmer; K Nikolics; F Hefti
Journal:  J Neurosci       Date:  1992-11       Impact factor: 6.167

6.  In vivo neurotrophic effects of GDNF on neonatal and adult facial motor neurons.

Authors:  Q Yan; C Matheson; O T Lopez
Journal:  Nature       Date:  1995-01-26       Impact factor: 49.962

7.  Nigral D1 and striatal D2 receptors mediate the behavioral effects of dopamine agonists.

Authors:  G J LaHoste; J F Marshall
Journal:  Behav Brain Res       Date:  1990-05-28       Impact factor: 3.332

8.  Complete nucleotide and deduced amino acid sequence of bovine phenylethanolamine N-methyltransferase: partial amino acid homology with rat tyrosine hydroxylase.

Authors:  E E Baetge; Y H Suh; T H Joh
Journal:  Proc Natl Acad Sci U S A       Date:  1986-08       Impact factor: 11.205

9.  Glial cell line-derived neurotrophic factor supports survival of injured midbrain dopaminergic neurons.

Authors:  K E Bowenkamp; A F Hoffman; G A Gerhardt; M A Henry; P T Biddle; B J Hoffer; A C Granholm
Journal:  J Comp Neurol       Date:  1995-05-15       Impact factor: 3.215

10.  GDNF protects nigral dopamine neurons against 6-hydroxydopamine in vivo.

Authors:  C M Kearns; D M Gash
Journal:  Brain Res       Date:  1995-02-20       Impact factor: 3.252

View more
  22 in total

1.  Functional regeneration in a rat Parkinson's model after intrastriatal grafts of glial cell line-derived neurotrophic factor and transforming growth factor beta1-expressing extra-adrenal chromaffin cells of the Zuckerkandl's organ.

Authors:  E F Espejo; M C Gonzalez-Albo; J P Moraes; F El Banoua; J A Flores; I Caraballo
Journal:  J Neurosci       Date:  2001-12-15       Impact factor: 6.167

2.  GDNF protection against 6-OHDA: time dependence and requirement for protein synthesis.

Authors:  C M Kearns; W A Cass; K Smoot; R Kryscio; D M Gash
Journal:  J Neurosci       Date:  1997-09-15       Impact factor: 6.167

Review 3.  Parkinson's disease: gene therapies.

Authors:  Philippe G Coune; Bernard L Schneider; Patrick Aebischer
Journal:  Cold Spring Harb Perspect Med       Date:  2012-04       Impact factor: 6.915

4.  Neurturin protects against 6-hydroxydopamine-induced reductions in evoked dopamine overflow in rat striatum.

Authors:  Wayne A Cass; Laura E Peters
Journal:  Neurochem Int       Date:  2010-07-06       Impact factor: 3.921

5.  Effects of ex vivo transduction of mesencephalic reaggregates with bcl-2 on grafted dopamine neuron survival.

Authors:  Caryl E Sortwell; William J Bowers; Scott E Counts; Mark R Pitzer; Matthew F Fleming; Susan O McGuire; Kathleen A Maguire-Zeiss; Howard J Federoff; Timothy J Collier
Journal:  Brain Res       Date:  2006-12-28       Impact factor: 3.252

6.  Orthotopic transplantation of immortalized mesencephalic progenitors (CSM14.1 cells) into the substantia nigra of hemiparkinsonian rats induces neuronal differentiation and motoric improvement.

Authors:  Stefan Jean-Pierre Haas; Stanislav Petrov; Golo Kronenberg; Oliver Schmitt; Andreas Wree
Journal:  J Anat       Date:  2007-11-23       Impact factor: 2.610

7.  Response of aged parkinsonian monkeys to in vivo gene transfer of GDNF.

Authors:  M E Emborg; J Moirano; J Raschke; V Bondarenko; R Zufferey; S Peng; A D Ebert; V Joers; B Roitberg; J E Holden; J Koprich; J Lipton; J H Kordower; P Aebischer
Journal:  Neurobiol Dis       Date:  2009-08-04       Impact factor: 5.996

8.  Parkinson's Disease: Surgical Options.

Authors:  Helen Bronte-Stewart
Journal:  Curr Treat Options Neurol       Date:  2003-03       Impact factor: 3.598

9.  Glial cell line-derived neurotrophic factor partially ameliorates motor symptoms without slowing neurodegeneration in mice with respiratory chain-deficient dopamine neurons.

Authors:  Fredrik H Sterky; Karin Pernold; Brandon K Harvey; Eva Lindqvist; Barry J Hoffer; Lars Olson
Journal:  Cell Transplant       Date:  2012-10-08       Impact factor: 4.064

10.  c-Jun mediates axotomy-induced dopamine neuron death in vivo.

Authors:  S J Crocker; W R Lamba; P D Smith; S M Callaghan; R S Slack; H Anisman; D S Park
Journal:  Proc Natl Acad Sci U S A       Date:  2001-10-30       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.